Product Description
Mechanisms of Action: APM1 Inhibitor,LTA4H Inhibitor,APN Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China
Approved Indications: None
Known Adverse Events: None
Company: Eiger BioPharmaceuticals
Company Location: PALO ALTO CA 94306
Company CEO: David A. Cory
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Lymphedema
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ULTRA | P2 |
Completed |
Lymphedema |
2018-10-01 |
|
| LIBERTY2 | P2 |
Terminated |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2018-03-01 |
|
| LIBERTY | P2 |
Completed |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2017-11-01 |
|
| CTR20232970 | N/A |
Unknown Status |
Hematopoietic Stem Cell Transplant|Leukemia|Myelodysplastic Syndrome|Multiple Myeloma |
None |